Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_74b7b50944d8e1960440fb1f5440b7fd |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-732 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70596 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3076 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-3061 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-56972 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5005 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-569 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08 |
filingDate |
2008-07-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate |
2009-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08faa99e0e8c88da363f02c0377b3b59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_20f753aad4fff8a7a7597b1ddfdff793 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7bfca2bdd6eccb0a523f44c96ddb93eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c9375b963976ca8ad134b2e3d0b4629 |
publicationDate |
2009-10-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-7598353-B2 |
titleOfInvention |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
abstract |
Cancer treatments use a therapy that: 1) interferes with the interaction between CD200 and its receptor to block immune suppression thereby promoting eradication of the cancer cells; and 2) directly kills the cancer cells either by complement-mediated or antibody-dependent cellular cytotoxicity or by targeting cells using a fusion molecule that includes a CD200-targeting portion. The therapy includes the administration of novel antibodies, functional fragments thereof or fusion molecules containing portions thereof. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9920123-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9447187-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11761963-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9180186-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2012106634-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9309305-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9862767-B2 |
priorityDate |
2000-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |